A fresh era of earnings growth may be on the horizon.
On July 8, 2026, Moderna, Inc. appointed veteran financial executive Michael McDonnell, former Biogen CFO, to its Board of Directors and Audit Committee, while a federal advisory panel previously ...
Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene Further improves 2026 and 2027 expected GAAP ...
Moderna's growth story is just beginning.
Stock surge explained: Moderna’s shares rose nearly 6% after reporting strong immune responses and safety in early hantavirus vaccine trials. Cruise outbreak toll: An Andes virus outbreak aboard MV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results